fda sued over tirzepatide Republican Administration Maintains Exclusivity Stance in GLP-1 (Tirzepatide) Compounding Dispute FDA declares Mounjaro, Zepbound shortage

Storage Conditions What's in the box

By prioritizing transparency, sourcing, and superior delivery systems, you can support your body's natural defenses without overwhelming your system

This data offers meaningful proof that a structured, clinically integrated GLP-1 strategy can deliver millions in real savings without compromising access or member outcomes.* Employer health strategies have traditionally centered on condition-specific programs to manage diseases like obesity, diabetes, and cardiovascular conditions individually, which has led to employers managing multiple point solutions simultaneously, often with low coordination, engagement, and return on investment

GLP-1 Receptor cAMP Cascade / Glucose Signaling Retatrutide (Triple) GIP Receptor Synergistic Metabolic Modulation Glucagon Rec

Mcbean et al., 2015

Some patients may find that one works better for them than the other